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Rebuilding the Damaged Heart
The Potential of Cytokines and Growth
Factors in the Treatment of Ischemic Heart Disease
Nirat Beohar, MD,*† Jonathan Rapp, MD,†‡ Sanjay Pandya, MD,† Douglas W. Losordo, MD*†§
Chicago, Illinois; and New Orleans, Louisiana
Cytokine therapy promises to provide a noninvasive treatment option for ischemic heart disease. Cytokines are
thought to influence angiogenesis directly via effects on endothelial cells or indirectly through progenitor cell-
based mechanisms or by activating the expression of other angiogenic agents. Several cytokines mobilize pro-
genitor cells from the bone marrow or are involved in the homing of mobilized cells to ischemic tissue. The re-
cruited cells contribute to myocardial regeneration both as a structural component of the regenerating tissue
and by secreting angiogenic or antiapoptotic factors, including cytokines. To date, randomized, controlled clinical
trials have not reproduced the efficacy observed in pre-clinical and small-scale clinical investigations. Neverthe-
less, the list of promising cytokines continues to grow, and combinations of cytokines, with or without concurrent
progenitor cell therapy, warrant further investigation. (J Am Coll Cardiol 2010;56:1287–97) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.039t
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Aytokine therapy is a promising, noninvasive treatment
pproach that may prevent cardiomyocyte loss or regenerate
amaged tissue. It may also be useful as an adjunctive
reatment to mechanical revascularization or cell therapy
nd for patients with disabling ischemia despite optimal
edical treatment. Cytokines are thought to benefit the
amaged heart through direct effects in the myocardium and
ndirectly by stimulating progenitor cells. Progenitor and
tem cells reside in the myocardium or are mobilized from
he bone marrow in response to cardiac ischemia, and
umerous reports indicate that these cells can be mobilized
herapeutically by cytokines (1–14). In the ischemic heart,
rogenitor cells can form a structural component of the
egenerating tissue—e.g., resident side-population cells (15)
nd lineage-negative, c-kit–positive cells (4) differentiated
nto endothelial cells, smooth-muscle cells, and cardiomy-
cytes in a murine model of myocardial infarction (MI).
he recruited cells also secrete angiogenic or anti-apoptotic
actors (16,17) that can maintain myocardial viability, ac-
elerate the recovery of ischemic myocardium, or amplify
unction in nonischemic regions (18,19). These observa-
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ccepted May 10, 2010.ions have led to the development of strategies that mobilize
rogenitor cells and enhance progenitor cell recruitment,
hereby preserving or replacing injured tissue (4). Impor-
antly, cytokines are pleiotropic, and their effects can be
ither beneficial or detrimental (Table 1) depending on the
ose and timing of administration. This review focuses on
everal cytokines that have displayed potentially beneficial
ffects in pre-clinical or clinical studies of ischemic heart
isease.
ytokine Agents
ibroblast growth factor (FGF). The FGF family com-
rises 22 polypeptides that promote angiogenesis and arte-
iogenesis by modulating the phenotypes of endothelial cells
nd vascular smooth muscle cells. FGF4 is encoded by the
eparin-binding secretory-transforming proto-oncogene
nd is not expressed in normal adult tissue. However, when
dministered to ischemic hearts, FGF4 stimulates endothe-
ial cell proliferation and the secretion of metalloproteinases,
rokinase-type plasminogen activator, and vascular endo-
helial growth factor (VEGF), which subsequently stimulate
ngiogenesis (20).
The AGENT (Angiogenic Gene Therapy) trials (Table 2)
xamined the effects of FGF in patients with coronary
rtery disease (CAD) and medically refractory angina.
n the first AGENT trial, intracoronary delivery of an
denovirus coding for FGF4 transcription (Ad5FGF-4)
as safe and appeared to improve exercise treadmill
imes (21). The phase 2 AGENT 2 trial tested whether
d5FGF-4 treatment improved regional myocardial perfu-ion (22). Patients administered Ad5FGF-4, but not placebo,
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tion in reversible and total perfu-
sion defect, but the results were
not statistically significant. The
phase 3 AGENT 3 and 4 trials
(23,24) enrolled patients with
Canadian Cardiovascular Society
(CCS) class 2 to 4 angina who
were unsuitable for mechanical
revascularization. Both trials were
halted prematurely when a
planned interim analysis of the
AGENT 3 cohort indicated that
the between-group difference in
the primary end point (treadmill
exercise duration 12 weeks after
treatment) would not reach sta-
tistical significance. Differences
in secondary outcomes (such as
change in CCS class or other
clinical variables) were also
nonsignificant.
Vascular endothelial growth
factor (VEGF). The VEGF cy-
tokines were among the first to
display protective or regenerative
effects in cardiac tissue. During
hypoxia, the therapeutic benefit of
VEGF occurs primarily through
the stimulation of endothelial cell
proliferation, migration, and sur-
vival, which subsequently leads to
neovascularization (25–30). The
extent of regeneration is deter-
mined by the tissue retention of
the administered isoform and by
the isoform’s affinity for VEGF re-
ceptors. Both endothelial cells and
hematopoietic stem cells (HSCs)
express VEGF receptors 1 and 2
(also known as Flt-1 and Flk-1,
respectively) (31,32), and the ex-
pression of VEGF receptors on
HSCs appears to be critical for
VEGF-dependent regulation of
ndothelial progenitor cells (EPCs) (33,34).
Treatment with VEGF protein-enhanced collateral
lood flow in animal models of chronic myocardial ischemia
35–38) and the safety and feasibility of VEGF therapy for
ngiogenesis has been assessed in several phase 1 studies
39–44). The VIVA (Vascular Endothelial Growth Factor
n Ischemia for Vascular Angiogenesis) trial was among the
rst large, phase 2 trials (Table 3) completed. Patients with
yocardial ischemia who were considered unsuitable for
echanical revascularization were randomized to receive
Abbreviations
and Acronyms
Ad5FGF  adenoviral
fibroblast growth factor
Ang  angiopoietin
CAD  coronary artery
disease
CCS  Canadian
Cardiovascular Society
CFI  collateral flow index
EPC  endothelial
progenitor cell
EPO  erythropoietin
FGF  fibroblast growth
factor
GCSF  granulocyte
colony-stimulating factor
GH  growth hormone
GMCSF  granulocyte-
macrophage colony-
stimulating factor
HGF  hepatocyte growth
factor
HIF  hypoxia-inducible
factor
HSC  hematopoietic stem
cell
IGF  insulin-like growth
factor
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PlGF  placental growth
factor
rhVEGF  recombinant
human vascular endothelial
growth factor
SCF  stem cell factor
SDF  stromal cell-derived
factor
VEGF  vascular
endothelial growth factorlacebo, low-dose recombinant human vascular endothelial arowth factor (rhVEGF), or high-dose rhVEGF by intra-
oronary infusion, followed by peripheral infusions 3, 6, and
days later (45). VEGF therapy was safe, but changes in
xercise treadmill time (the primary end point) did not differ
ignificantly between groups at the 2-month follow-up visit.
our months after treatment, the only statistically signifi-
ant finding was the proportion of high-dose VEGF pa-
ients who improved by at least 1 CCS class (p  0.05 vs.
lacebo). In the Euroinject One trial (46), patients with
CS class 3 or 4 angina were randomized to receive 0.5-mg
njections of either VEGF-A165 plasmid or a placebo
lasmid into myocardial regions that displayed stress-
nduced perfusion defects. At the 3-month follow-up visit,
he perfusion defects did not differ between treatment
roups, but VEGF treatment was associated with improve-
ents in local wall motion. Intracoronary VEGF gene
ransfer was also evaluated in the KAT (Kuopio Angiogen-
sis Trial) (47). Upon initiation of percutaneous coronary
ntervention (PCI), patients with CCS class 2 or 3 angina
90% of whom received stents) were randomized to receive
ntracoronary injections of adenovirus-encoded VEGF165,
EGF165 plasmid liposome, or Ringer’s lactate. Six months
fter treatment, there were no significant differences among
he 3 treatment groups in functional status, but myocardial
erfusion improved in patients treated with adenoviral
EGF.
ranulocyte colony-stimulating factor (GCSF). GCSF
s a potent hematopoietic cytokine that influences the
evelopment and function of granulocytes and mobilizes
rogenitor cells from the bone marrow (48). Progenitor cell
obilization appears to be initiated when GCSF binds to
eceptors on the cell surface, which leads to the release of
nzymes that digest adhesion molecules (49). GCSF also
irectly influences the activity of some nonhematopoietic
ells, such as cardiomyocytes and endothelial cells (50).
hen administered shortly after MI, GCSF activates the
anus kinase/signal transducer and activator of transcription
athway, which stimulates the production of several anti-
poptotic proteins, decreases cardiomyocyte death, and
imits infarct size (51). In a murine model of MI, GCSF
reatment was associated with improvements in left ventric-
lar function and enhanced arteriogenesis (52). However,
CSF can also stimulate the differentiation of lineage-
ommitted progenitor cells into neutrophils and macro-
hages (53), which could worsen inflammation and cardiac
emodeling (54).
In phase 1 trials, GCSF administration after PCI for
cute MI appeared to improve cardiac function (50,55–58).
atients in the randomized, open-label FIRSTLINE-AMI
Front-Integrated Revascularization and Stem Cell Libera-
ion in Evolving Acute Myocardial Infarction) trial received
daily subcutaneous GCSF injections starting within
0 min after primary PCI for ST-segment elevation MI;
he control group did not receive placebo injections but
ad identical post-interventional care. Four months (56)
nd 1 year (55) after the PCI procedure, improvements in
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October 12, 2010:1287–97 Cytokine Therapy for Ischemic Heart Diseaseeft ventricular ejection fraction (LVEF) were significantly
reater in GCSF-treated patients than in the control group.
nfortunately, these promising results were not repro-
uced in subsequent double-blind, placebo-controlled trials
59–61) (Table 4).
Several nonrandomized studies have investigated the use
f GCSF for treatment of chronic ischemic heart disease
Table 5). Hill et al. (62) administered 5 daily subcutaneous
njections of GCSF to patients with CAD and angina. The
reatment produced large increases in the number of circu-
ating progenitor cells, but there was no improvement in
gentsTable 1 Agents
Agent Molecular Targets
VEGF VEGF receptors on endothelial cells,
monocytes, and HSCs
Stimula
tube
Mobilize
and d
PlGF VEGF receptor 1 Cross-ta
Mobilize
FGF FGF receptors on endothelial cells,
smooth muscle cells, and myoblasts
Stimula
GCSF GCSF receptors on hematopoietic and
nonhematopoietic cells
Inhibits
Activate
Synergis
Mobilize
Accelera
Possible
stem
GMCSF GMCSF receptors on granulocyte and
monocyte precursor cells and
monocytes
Stimula
Activate
Mobilize
SCF c-kit Synergis
facto
Mobilize
Angiopoietin-1 TIE2 receptors on endothelial cells Enhance
stabi
Mobilize
HGF c-Met receptor on numerous cells (e.g.,
endothelial cells, cardiac myocytes,
progenitor cells)
Attracts
GH/IGF-1 IGF receptor on vascular and satellite
cells, cardiac stem cells
Enhance
regen
Erythropoietin Erythropoietin receptor on HSCs, EPCs,
endothelial cells, and cardiac
myocytes
Promote
Mobilize
CS acute coronary syndrome; EPC endothelial progenitor cell; FGF fibroblast growth factor;
olony-stimulating factor; HGF hepatocyte growth factor; HPC hematopoietic progenitor cell; H
Imyocardial infarction; PlGF placental growth factor; SCF stem cell factor; SDF stromal
g-like loops and Epidermal growth factor homology domains-2; VEGF  vascular endothelial growVEF, left ventricular wall motion, myocardial perfusion, tr treadmill exercise time 1 month after treatment. Wang et
l. (63) administered subcutaneous injections of GCSF for
days to 13 prospectively selected patients with severe
cclusive CAD. CCS class improved from baseline to the
-month follow-up visit, but the number of single-photon
mission computed tomography image segments with per-
usion defects either at rest or under stress was unchanged
nd LVEFs declined, perhaps because GCSF-mobilized
eukocytes increased inflammation and fibrosis. Notably,
rogenitor cell mobilization was considerably lower in
patients who were considered “poor mobilizers” than in
ts/Mechanism Potential Detrimental Effects
liferation, migration, and
tion
s; improves EPC survival
tiation
Tumorigenesis
Retinopathy
Flushing (protein infusion)
Hypotension (protein infusion)
VEGF receptor 2
s and HSCs
Associated with carotid atherosclerotic plaque
destabilization and adverse outcomes
in ACS
Associated with depressed LV function in
ischemic cardiomyopathy (exact role
undefined)
liferation Membranous nephropathy
Dose-related hypotension
Coronary plaque destabilization
Accelerated atherosclerosis
sis
AK-STAT pathway
h SDF-1
s and granulocytes
ound healing post-MI
ts on resident cardiac
Tumorigenesis
Dysregulated inflammation leading to
impaired wound healing or plaque
destabilization
Medullary bone pain
eriogenesis
ocytic cells
s and HSCs
Infarct expansion through alteration of
inflammation (i.e., dendritic cell function)
Plaque destabilization/acute MI
“First-dose reaction”: dyspnea, hypotension,
hypoxia, tachycardia, or syncope
Bone pain
Peripheral edema, pericardial effusion
h colony-stimulating
marrow precursor cells
Mast cell degranulation/wheal formation
at injection site
Hyperpigmentation
Allergic-like reaction including respiratory
distress
el maturation and
s and HPCs
Enhanced renal inflammation and fibrosis
Pulmonary hypertension
Adverse vascular remodeling or angiogenesis
nt cardiac stem cells Tumorigenesis
Retinopathy
etal and cardiac muscle
n
Retinopathy
Diarrhea
Hypotension
Hypoglycemia
survival
s
May accelerate death in patients with cancer
Hypertension, headache, arthralgias, and
nausea
MI (rare)
granulocyte colony-stimulating factor; GH growth hormone; GMCSF granulocyte-macrophage
ematopoietic stem cell; IGF insulin-like growth factor; JAK Janus kinase; LV left ventricular;
ived factor; STAT signal transducers and activators of transcription; TIE2 Tyrosine kinase with
or.Effec
tes pro
forma
s EPC
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lk with
s EPC
tes pro
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s the J
tic wit
s HSC
tes w
effec
cells
tes art
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s EPC
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s vess
lity
s EPC
reside
s skel
eratio
s cell
s EPC
GCSF
SC hhe 9 remaining patients who were considered “mobilizers.”
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Cytokine Therapy for Ischemic Heart Disease October 12, 2010:1287–97he mobilizers, but not the poor mobilizers, experienced
ignificant improvements in nitroglycerin use and angina
requency. These findings indicate that the potential benefit
f GCSF therapy requires progenitor cell mobilization.
GCSF treatment did not worsen inflammation in several
tudies of patients with acute MI (50,55,56,58 – 61), and
andomized, Double-Blind Trials of FGFTable 2 Randomized, Double-Blind Trials of FGF
Grines et al. (21)
Agent
Grines e
Age
Phase 1 2
Patients Chronic CAD, LVEF 40%,
CCS class 2–3
Chronic CAD, LV
CCS class 4
Therapy Ad5FGF-4 Ad5FGF-4
Delivery route Intracoronary Intracoronary
Duration of follow-up 12 weeks 8 weeks
Primary end point Safety and feasibility  RPDS
Assessment modality Clinical and exercise treadmill test Adenosine SPEC
Secondary end point  Exercise time  Defect size
Treatment groups FGF (n  60)
Placebo (n  19)
FGF (n  35)
Placebo (n  17
Dose 108.5–1010.5 vp 1010 vp
Findings Trend toward1 in exercise time
with therapy
Lower rates of r
at 1 year wit
RPDS with th
baseline to fo
change in CC
primary end
Notes — One outlier in p
had 50%2
p  0.05.
Ad  adenoviral; CAD  coronary artery disease; CCS  Canadian Cardiovascular Society; ETT 
ot applicable; QOL  quality of life; RPDS  reversible perfusion defect size; SPECT  single-ph
hase 2 VEGF TrialsTable 3 Phase 2 VEGF Trials
Henry et al. (45) VIVA
Patients Stable angina, “no-option” CAD
Therapy Recombinant human VEGF
Duration of follow-up 60 days, 120 days
Primary end point  ETT at 60 days
Secondary end points  ETT, angina, and myocardial perfusion at
day 120
Treatment groups High-dose (n  59)
Low-dose (n  56)
Placebo (n  63)
Dosage High-dose: 50 ng/kg per min IC for 20 min†
Low-dose: 17 ng/kg per min IC for 20 min†
Findings 2 in angina class at day 120 in high-dose
group compared with placebo*;
no benefit in ETT
p  0.05. †Followed by 4-h infusions on days 3, 6, and 9.
Adv adenovirus vector; IC intracoronary; PCI percutaneous coronary intervention; PFU plaque-fo
s in Table 2.he rate of restenosis did not differ significantly between
CSF and control patients in the randomized, open-label,
IRSTLINE-AMI trial (55,56) or in 3 randomized, double-
lind, placebo-controlled studies (i.e., the STEMMI [Stem
ells in Myocardial Infarction], REVIVAL-2 [22 Regen-
rate Vital Myocardium by Vigorous Activation of Bone
3) Henry et al. (24)
Agent 3
Henry et al. (24)
Agent 4
3 3
0%, CAD not requiring immediate
revascularization,
LVEF 30%, CCS class 2–4
(U.S.)
“No-option” CAD patients,
LVEF 30%, CCS class 2–4
(Europe, Latin America,
Canada)
Ad5FGF-4 Ad5FGF-4
Intracoronary Intracoronary
12 weeks 12 weeks
 ETT  ETT
Exercise treadmill test Exercise treadmill test
 CCS class, coronary events, or death at 1 year,  QOL, time to
ST-segment depression during exercise, proportion of patients
with 30% increase in ETT
High-dose (n  140)
Low-dose (n  137)
Placebo (n  139)
High-dose (n  35)
Low-dose (n  43)
Placebo (n  38)
High-dose: 1010 vp
Low-dose: 109 vp
Placebo  NA
High-dose: 1010 vp
Low-dose: 109 vp
Placebo  NA
larization
py.2 in
from
p*; no
e (not
Potential therapeutic benefit
among older patients with
more severe angina
—
Pooled analysis: placebo effect much greater in men than women.
Women had improved CCS class and ETT with therapy*
group
S
Enrollment ended early when interim analysis indicated that the
primary end point was unlikely to differ significantly between
groups
ise treadmill time; FGF  fibroblast growth factor; LVEF  left ventricular ejection fraction; NA 
ission computed tomography; vp  viral particles;   change;1  increase;2  decline.
Hedman et al. (47) KAT Kastrup et al. (46) Euroinject One
CAD undergoing PCI Severe, stable angina; “no-option” CAD
PL VEGF Plasmid VEGF
ths 3 months
al lumen diameter, % stenosis  Myocardial perfusion
rdial perfusion, exercise tolerance,
dence of new cardiac events,
ascularization, functional class
Safety, wall motion, LVEF, angina
 37)
 28)
o (n  38)
VEGF-A165 (n  40)
Placebo (n  40)
 1010 PFU IC
00 g IC
VEGF-A165: 0.5 mg
erfusion at 6 months compared
baseline in Ad group*; no
erences among groups
Improved regional wall motion in VEGF
group compared with placebo*t al. (2
nt 2
EF 3
T
)
evascu
h thera
erapy
llow-u
S scor
point)
lacebo
in RPDStable
Ad or
6 mon
Minim
Myoca
inci
rev
Adv (n
PL (n
Placeb
Adv: 2
PL: 2,0
1 in p
with
diffrming unit; PL plasmid liposome; VEGF vascular endothelial growth factor; other abbreviations
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October 12, 2010:1287–97 Cytokine Therapy for Ischemic Heart Diseasearrow Stem Cells], and G-CSF-STEMI [Granulocyte
olony-Stimulating Factor ST-Segment Elevation Myo-
ardial Infarction] trials) (59–61). However, Kang et al.
64) found restenosis in 2 of 3 patients who received GCSF
lone as adjunctive therapy to primary PCI and in 5 of 7
atients who received both GCSF and infused progenitor
ells as adjunctive treatments. This may have occurred
ecause PCI was performed 4 days after GCSF injection,
hen GCSF-induced leukocytosis and the subsequent in-
ammatory response was peaking. In an uncontrolled study
65), patients received GCSF therapy 2 days after primary
CI, followed 4 days later by the collection and intracoro-
ary injection of mobilized progenitor cells; restenosis was
eported in 8 of 20 patients, and 2 patients experienced MI
etween 2 and 6 months after treatment.
Among 122 patients in 4 studies who received GCSF
herapy soon after acute MI (50,57,60,61), 2 died during the
ollow-up periods (50,61), another experienced subacute
tent thrombosis (60), and a fourth patient underwent
mergency splenectomy for spontaneous splenic rupture
andomized Controlled GCSF Trials* in Patients With Acute MITable 4 Randomized Controlled GCSF Trials* in Patients With
Treatment Group
Valgimigli
et al. (58)
Ince et al. (56)
FIRSTLINE-AMI
GCSF Control GCSF Control†
GCSF dosage 5 g/kg/day for
4 days beginning
37 66 h after
symptom onset
10 g/kg/day for
6 days beginning
85 30 min after
reperfusion
Duration of follow-up 6 months 4 months
n 10 10 25 25
LVEF Increased Increased Increased Unchanged
Perfusion Increased Increased NR NR
LVEDV Unchanged Unchanged Unchanged Declined
LVESV NR NR NR NR
Wall thickening NR NR Increased Increased
arameters displaying significantly better performance than was observed in the alternative treatm
ither insignificant (p  0.05) or the significance was not reported. *Double-blind: Ripa et al. (60)
l. (56). †No placebo treatment. ‡Decreased infarct size.
AMI  acute myocardial infarction; GCSF  granulocyte colony-stimulating factor; LVEDV  l
nd-systolic volume; NR  not reported.
CSF Trials in Patients With Chronic Ischemic Heart DiseaseTable 5 GCSF Trials in Patients With Chronic Ischemic Heart D
Treatment Groups
Wang et al. (63)
GCSF Control
GCSF dosage 5 g/kg/day for 6 days
Cell therapy None
Duration of follow-up 2 months
End point assessment SPECT, MRI, echocardiography
n 13 16
LVEF Decreased Decreased
Perfusion Unchanged Unchanged
LVEDV Decreased Increased
LVESV Increased Increased
Myocardial ischemia Decreased Increasedignificant (p  0.05), within-group changes from baseline to follow-up are identified with italicized text.
MRI  magnetic resonance imaging; SPECT  single-photon emission computed tomography; other a57). Wang et al. (63) found no serious vascular adverse
vents in 13 patients who received GCSF therapy for
reatment of severe ischemic heart disease. However, Hill et
l. (62) and Boyle et al. (66) reported serious vascular
dverse events in 2 of 16 patients with CAD and in 1 of 5
atients with chronic ischemic heart disease, respectively,
fter GCSF treatment. There is no evidence of GCSF-
nduced arrhythmia in clinical trials of patients with isch-
mic heart disease, and the results from some animal studies
uggest that GCSF treatment may improve electrical
tability (67).
ranulocyte-macrophage colony-stimulating factor (GMCSF).
MCSF stimulates the growth and differentiation of gran-
locyte and macrophage precursor cells, induces peripheral
onocytosis, impedes monocyte apoptosis (5,68), and in-
reases the number of circulating EPCs, which may then
articipate in regenerative activity (69). In patients with
AD who received a single intracoronary injection of
MCSF, followed by subcutaneous injections every other
ay for 2 weeks afterward, GMCSF was associated with
MI
Ripa et al. (60)
STEMMI
Zohlnhöfer et al. (61)
REVIVAL-2
Engelmann et al. (59)
G-CSF-STEMI
CSF Control GCSF Control GCSF Control
g/kg/day for
days beginning
–2 days after AMI
10 g/kg/day for
5 days beginning
5 days after AMI
10 g/kg/day for
5 days beginning
6 h to 7 days after
symptom onset
6 months 4–6 months 3 months
39 56 58 23 21
eased Increased Increased Increased Increased Increased
NR Increased‡ Increased‡ Unchanged Unchanged
eased Increased Decreased Decreased Increased Increased
reased Decreased Decreased Decreased Decreased Decreased
eased Increased NR NR Increased Increased
oup are identified with bold italicized text. Within-group changes from baseline to follow-up were
höfer et al. (61), and Engelmann et al. (59); single-blind: Valgimigli et al. (58); open-label: Ince et
tricular end-diastolic volume; LVEF  left ventricular ejection fraction; LVESV  left ventricular
e
Hill et al. (62) Boyle et al. (66)
GCSF GCSF
10 g/kg/day for 5 days 10 g/kg/day for 4 days
None Intracoronary infusion
1 month 12 months
MRI Angiography
16 5
Decreased Increased
Increased Increased
NR NR
NR NR
Increased DecreasedAcute
G
10
6
1
39
Incr
NR
Incr
Dec
Incr
ent gr
, Zohlniseasbbreviations as in Table 4.
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Cytokine Therapy for Ischemic Heart Disease October 12, 2010:1287–97ignificant improvement in electrocardiographic signs of
yocardial ischemia during coronary balloon occlusion and
ith significant improvement in collateral flow index (CFI).
FI was unchanged in patients who received placebo
njections. These benefits likely evolved from cytokine-
nduced angiogenesis or changes in collateral vascular tone,
ather than through a progenitor cell–mediated mechanism,
ecause the mobilization of progenitor cells was low. Im-
rovements in CFI were also reported in a subsequent study
f GMCSF therapy, but 2 of 7 GMCSF-treated patients
xperienced acute MI during the 2-week course of therapy
70). Furthermore, in animal studies of MI, cardiac remod-
ling worsened after treatment with romurtide to induce
MCSF expression (68,71). Thus the mechanism of action
nd potential inflammatory consequences associated with
MCSF must be better understood and controlled before
arger human trials can be considered.
rythropoietin (EPO). EPO is involved in both angio-
enesis and progenitor/stem cell development. Numerous
issues produce EPO in response to hypoxia and metabolic
tress though a mechanism mediated by hypoxia-inducible
actor (HIF)-1, and activation of the EPO receptor inhibits
poptosis (72). EPO is also believed to enhance angiogen-
sis by increasing the proliferation of endothelial cells and
y mobilizing bone marrow–derived cells, including EPCs
73). A long-acting EPO analog, darbepoetin alpha, was
afely administered to patients with acute MI but provided
o functional benefit (74,75). The administration of EPO
o patients with acute MI continues to be investigated in the
ngoing HEBE III (Intracoronary Infusion of Autologous
ononuclear Bone Marrow Cells or Peripheral Mononu-
lear Blood Cells After Primary Percutaneous Coronary
ntervention) and REVEAL (Reduction of Infarct Expan-
ion and Ventricular Remodeling With Erythropoietin
fter Large Myocardial Infarction) trials (NCT00378352,
linicalTrials.gov) (76).
rowth hormone (GH) and insulin-like growth factor
IGF)-1. GH is synthesized by the anterior pituitary gland,
nd the binding of GH to receptors in the myocardium
ncreases IGF-1 synthesis (77). Experimental evidence has
ong suggested a role for the GH/IGF signaling in the
yocardium (8). In experimental models of MI, subcuta-
eous injections of GH significantly increased hypertrophy
f the viable myocardium and improved left ventricular
ystolic function without increasing collagen deposition or
brosis (78,79). Moreover, cardiac stem cells have been
hown to possess growth factor receptors that may partici-
ate in the activation of these cells for cardiac repair (9).
he effect of GH on myocardial growth, cardiac function,
nd IGF-1 levels in patients with nonischemic or ischemic
ardiomyopathy, and in mixed patient populations, has been
nvestigated in several small studies (80–85). Collectively,
he findings suggest that additional investigations with GH
r IGF-1 are warranted, despite concerns about retinopathy
nd other potential long-term side effects. angiopoietin (Ang). Ang1, Ang2, and Ang3/4 are be-
ieved to control the remodeling and stabilization of vessels
uring the later stages of adult vascular development
86,87). Ang1 is a Tyrosine kinase with Ig-like loops and
pidermal growth factor homology domains-2 (TIE2) ag-
nist that promotes vessel survival, inhibits vascular damage,
uppresses inflammatory gene expression, and stimulates
essel remodeling and angiogenesis (88). In rats, Ang1
dministration after acute MI increased vascular density,
nd the vessels appeared to be relatively mature, with
arger-sized lumens (89). In a swine model of chronic
schemia, perfusion improved significantly 4 weeks after
ng1 administration, and the improvement was sustained
hrough week 12 (90). Curiously, Ang1 activity seems to
ppose VEGF-induced angiogenesis (91). Ang2 acts as a
IE2 agonist in EPCs, which increases angiogenesis (92),
ut primarily antagonizes TIE2 in vascular endothelial cells,
hereby reducing endothelial integrity, increasing vessel
ermeability, and inducing vessel destabilization and re-
odeling through, in part, the suppression of Ang1-
ediated activity (93). Thus the influence of Ang2 on
ndothelial cell activity and, by extension, angiogenesis is
omplex and context-dependent. To date, none of the
ngiopoietins have been investigated for treatment of isch-
mic heart disease in clinical studies.
epatocyte growth factor (HGF). HGF is a pluripotent
rowth factor synthesized by the liver. Both HGF and the
GF receptor c-Met can be found in the heart, and cardiac
GF levels are up-regulated after MI in both animal
odels and human subjects (94). HGF can induce both
ro-angiogenic and antiapoptotic effects and is believed to
educe detrimental remodeling after MI (95). HGF has yet
o be investigated for cardiac repair in humans.
lacental growth factor (PlGF). PlGF is a member of the
EGF family of cytokines (96) and directly influences
ngiogenesis by binding to VEGF receptor-1, transactivat-
ng VEGF receptor-2, and enhancing VEGF activity (97).
lGF mediates endothelial cell growth, survival, and migra-
ion (98,99); mobilizes hematopoietic progenitor cells from
he bone marrow; is chemotactic for monocytes and mac-
ophages (2,100,101); and may induce monocytes to release
ytokines that increase the homing of stem cells to the
njured myocardium (102). Results from pre-clinical inves-
igations suggest that PlGF can improve myocardial perfu-
ion (11,103); however, adenoviral PlGF therapy was asso-
iated with greater atherosclerotic intimal thickening and
dventitial neovascularization (104). Before clinical trials
an be initiated, additional pre-clinical studies must dem-
nstrate that PlGF can induce neovascularization without
orsening atherosclerosis.
tem cell factor (SCF). SCF is the ligand of c-kit
CD117), a proto-oncogene receptor tyrosine kinase that is
xpressed on adult HSCs (105–107). Activation of the c-kit
eceptor (107–110) is required for the mobilization of
-kit–positive HSCs and EPCs, and c-kit–positive cells favor-
bly impact cardiac remodeling both directly, through the
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ectly, through an increase in neoangiogenesis (4,111–117).
CF acts synergistically with colony-stimulating factors to
obilize bone marrow-derived stem cells (106,118), improves
he homing of c-kit–positive bone marrow-derived cells (118),
nd enhances the migration of resident cardiac stem cells to the
eri-infarct zone (119). Combined SCF and GCSF therapy
ncreased myocardial blood flow, but not function, after cir-
umflex artery ligation in baboons (120), and treatment with
CF, GCSF, or both (compared with placebo) reduced mor-
ality in a murine model of MI, but SCF therapy alone did not
mprove left ventricular performance or remodeling (121). The
enefits of combined SCF and GCSF treatment have also
een reported in a mouse infarct-reperfusion model (122).
ractical Considerations
iming of therapy. The cellular environment of infarcted
yocardium is dynamic, so the timing of cytokine admin-
stration is a necessary consideration during treatment. For
xample, the number of GCSF receptors on cardiomyocytes
ncreases markedly soon after MI in rats (51), and prompt
CSF administration has been associated with declines in
ardiomyocyte apoptosis, smaller infarct areas, and de-
reased ventricular dilation (51,123,124), whereas delayed
SCF treatment aggravated left ventricular remodeling in a
orcine myocardial-reperfusion model (124). Four clinical
rials of GCSF therapy administered at different time points
nd for different durations after MI yielded different pat-
erns of efficacy (55,60,61,64).
The time-dependent effects of cytokine administration
fter MI could be either direct or related to the recruitment
f bone marrow-derived progenitor cells. The activity of
one marrow-derived cells may differ depending on the state
f the infarcted myocardium, and the expression of cell-
ignaling molecules may change over time. Wang et al. (30)
ound that the expression of VEGF and stromal cell-derived
actor (SDF)-1, which is involved in the homing of pro-
enitor cells to ischemic tissue, is not acutely elevated in
schemic myocardium (30), and that human plasma levels of
DF-1, VEGF-A, and FGF-2 reach maximum concentra-
ions 2 to 3 weeks after MI (125). In a murine MI model,
ytokines involved in progenitor-cell homing, including
DF-1, were up-regulated immediately after MI, then
own-regulated over a 7-day period, and the delayed ad-
inistration of GCSF (56 days after MI) improved remod-
ling only when SDF-1 expression was enhanced in the
nfarcted tissue. These observations imply that the effective-
ess of cell-mobilizing agents for treatment of MI may
epend on the early, cytokine-mediated recruitment of
obilized stem cells to the injured myocardium (126,127).
afety. Because angiogenic inhibitors can reverse or reduce
he formation of atherosclerotic plaques in animal models
128,129), the pro-angiogenic activity of cytokines could, in
heory, worsen plaque formation or contribute to plaque
estabilization (as noted in the studies of GCSF, GMCSF, rnd PlGF described above). However, successful angiogenic
herapy may enhance re-endothelialization after vascular
njury and, consequently, impede plaque formation by
uppressing neointimal thickening (130). The long-term
heoretical concerns associated with therapeutic angiogene-
is include an increased risk for neoplastic disease and the
nduction or worsening of retinopathy. No evidence of a link
etween angiogenic cytokines and tumor development or
etinopathy has been reported in clinical trials (131), but
andidate patients must be adequately screened and moni-
ored for malignancies, premalignant conditions, and
etinopathy.
eperfusion injury. In most published animal studies, MI
as induced by ligating the coronary artery, which perma-
ently halts blood flow. However, blood flow is restored in
linical presentations of MI, so the ischemia-reperfusion
odels used by Beohar et al. (124) and Dawn et al. (122)
ore closely reproduce the clinical experience. The release
f cell-homing factors may differ in chronically ischemic and
eperfused cells and could influence the recruitment of
rogenitor cells to the injured tissue. In addition, early,
ustained reperfusion has been shown to reduce left ventric-
lar remodeling after MI (62,132), and this benefit could
bscure the effects of cytokine administration in clinical
rials.
ummary and Future Directions
ytokine therapy could provide an attractive treatment
ption for many cardiovascular diseases. Although the
utcomes from clinical trials of cytokine therapy have failed
o meet expectations, combinations of cytokines, with or
ithout concurrent progenitor cell therapy, or the admin-
stration of agents (e.g., HIF-1 alpha, Sonic hedgehog) that
p-regulate several angiogenic factors simultaneously, war-
ant further investigation. For patients with chronic CAD,
herapy that combines progenitor cell-mobilizing agents
ith the elevated expression of cell-homing factors (e.g.,
DF-1) in ischemic tissue may be particularly valuable. The
ffectiveness of regenerative therapies could also be im-
roved by a more complete understanding of the cellular
nvironment after MI. The growth factors IGF-1 (133) and
GF (134) induce expression of collagen-degrading met-
lloproteinases that could make the extracellular matrix
ore amenable to progenitor cell migration, and researchers
ave begun to investigate other agents that modulate the
nterstitial matrix, including the matrix protein Del-1,
hich coordinates integrin expression (135), and Cyr61,
hich induces angiogenesis by binding to av5 (136).
pproaches that combine cytokine and cell therapy can be
efined by continuing to characterize the relevant signaling
athways, the optimal magnitude of progenitor cell mobi-
ization, the relative efficiency of subpopulations of bone
arrow–derived cells, and the potential importance ofesident cardiac progenitor cells (9).
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